• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
An Open-Label, Multi-Institutional, Randomized Study to Evaluate the Additive Effect of a Leukotriene Receptor Antagonist on Cough Score in Patients with Cough-Variant Asthma Being Treated with Inhaled Corticosteroids.一项开放标签、多机构、随机研究，旨在评估白三烯受体拮抗剂对接受吸入性糖皮质激素治疗的咳嗽变异性哮喘患者咳嗽评分的附加效应。
Kobe J Med Sci. 2018 Dec 4;64(4):E134-E139.
2
Retrospective, observational study of different medication regimens and outcome in children with cough variant asthma.回顾性观察研究不同药物治疗方案对咳嗽变异性哮喘患儿的疗效。
Immun Inflamm Dis. 2024 Aug;12(8):e1357. doi: 10.1002/iid3.1357.
3
Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: A systematic review.每日吸入皮质类固醇或孟鲁司特治疗学龄前儿童哮喘或反复喘息：系统评价。
Pediatr Pulmonol. 2018 Dec;53(12):1670-1677. doi: 10.1002/ppul.24176. Epub 2018 Nov 5.
4
Effectiveness of montelukast in the treatment of cough variant asthma.孟鲁司特治疗咳嗽变异性哮喘的有效性
Ann Allergy Asthma Immunol. 2004 Sep;93(3):232-6. doi: 10.1016/S1081-1206(10)61493-7.
5
Comparison of leukotriene receptor antagonists in addition to inhaled corticosteroid and inhaled corticosteroid alone in the treatment of adolescents and adults with bronchial asthma: a meta-analysis.白三烯受体拮抗剂联合吸入性皮质类固醇与单独吸入性皮质类固醇治疗青少年和成人支气管哮喘的疗效比较：一项荟萃分析。
Asian Pac J Allergy Immunol. 2012 Jun;30(2):130-8.
6
Effects of treatment with montelukast alone, budesonide/formoterol alone and a combination of both in cough variant asthma.孟鲁司特单药治疗、布地奈德/福莫特罗单药治疗与两者联合治疗对咳嗽变异性哮喘的影响。
Respir Res. 2022 Oct 10;23(1):279. doi: 10.1186/s12931-022-02114-6.
7
Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.长效β2受体激动剂与抗白三烯药物作为吸入性糖皮质激素治疗慢性哮喘的附加疗法比较
Cochrane Database Syst Rev. 2005 Jan 25(1):CD003137. doi: 10.1002/14651858.CD003137.pub2.
8
Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).孟鲁司特或沙美特罗联合吸入性糖皮质激素治疗成人哮喘：一项随机、双盲对照研究的设计与原理（孟鲁司特作为辅助治疗药物的IMPACT研究）
Respir Med. 2000 Jun;94(6):612-21. doi: 10.1053/rmed.2000.0806.
9
Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.长效β2受体激动剂与抗白三烯药物作为吸入性糖皮质激素治疗慢性哮喘的附加疗法比较
Cochrane Database Syst Rev. 2006 Oct 18(4):CD003137. doi: 10.1002/14651858.CD003137.pub3.
10
Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.孟鲁司特，一种白三烯受体拮抗剂，用于治疗2至5岁儿童的持续性哮喘。
Pediatrics. 2001 Sep;108(3):E48. doi: 10.1542/peds.108.3.e48.

引用本文的文献

1
Cough-Variant Asthma: A Review of Clinical Characteristics, Diagnosis, and Pathophysiology.咳嗽变异性哮喘：临床特征、诊断及病理生理学综述
J Allergy Clin Immunol Pract. 2025 Mar;13(3):490-498. doi: 10.1016/j.jaip.2024.11.005. Epub 2024 Nov 16.
2
Mechanisms of Er Chen Tang on Treating Asthma Explored by Network Pharmacology and Experimental Verification.网络药理学与实验验证探讨二陈汤治疗哮喘的作用机制。
Comb Chem High Throughput Screen. 2024;27(2):227-237. doi: 10.2174/1386207326666230503112343.
3
Latent myofascial trigger points injection therapy for adult cough variant asthma: A randomized controlled trial.成人咳嗽变异性哮喘的潜伏性肌筋膜触发点注射疗法：一项随机对照试验。
Front Med (Lausanne). 2023 Feb 23;10:937377. doi: 10.3389/fmed.2023.937377. eCollection 2023.
4
Study on the Relationship Between Bronchoalveolar Lavage Fluid Cell Count, Th1/Th2 Cytokines and Pulmonary Function in Patients with Cough Variant Asthma.咳嗽变异性哮喘患者支气管肺泡灌洗液细胞计数、Th1/Th2细胞因子与肺功能的关系研究
J Asthma Allergy. 2022 Nov 24;15:1713-1720. doi: 10.2147/JAA.S383128. eCollection 2022.
5
Narrative Review of the Mechanisms and Treatment of Cough in Asthma, Cough Variant Asthma, and Non-asthmatic Eosinophilic Bronchitis.哮喘、咳嗽变异性哮喘和非哮喘性嗜酸性粒细胞性支气管炎咳嗽的机制和治疗的叙述性综述。
Lung. 2022 Dec;200(6):707-716. doi: 10.1007/s00408-022-00575-6. Epub 2022 Oct 13.
6
Objective and Subjective Measurement of Cough in Asthma: A Systematic Review of the Literature.哮喘咳嗽的客观和主观测量：文献系统评价。
Lung. 2022 Apr;200(2):169-178. doi: 10.1007/s00408-022-00527-0. Epub 2022 Apr 13.
7
The effect of montelukast sodium plus budesonide on the clinical efficacy, inflammation, and pulmonary function in children with cough variant asthma.孟鲁司特钠联合布地奈德对咳嗽变异性哮喘患儿临床疗效、炎症及肺功能的影响
Am J Transl Res. 2021 Jun 15;13(6):6807-6816. eCollection 2021.
8
Retrospective Study of the Effects of Post-nasal Drip Symptoms on Cough Duration.鼻后滴注症状对咳嗽持续时间影响的回顾性研究。
In Vivo. 2021 May-Jun;35(3):1799-1803. doi: 10.21873/invivo.12440.
9
Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence.孟鲁司特药物可能改善新冠预后：证据综述
Front Pharmacol. 2020 Sep 4;11:1344. doi: 10.3389/fphar.2020.01344. eCollection 2020.

本文引用的文献

1
Clinical, physiological and anti-inflammatory effect of montelukast in patients with cough variant asthma.孟鲁司特治疗咳嗽变异性哮喘患者的临床、生理和抗炎作用。
Respiration. 2012;83(4):308-15. doi: 10.1159/000332835. Epub 2011 Nov 17.
2
Antitussive effects of the leukotriene receptor antagonist montelukast in patients with cough variant asthma and atopic cough.孟鲁司特钠治疗咳嗽变异性哮喘和变应性咳嗽患者的镇咳作用。
Allergol Int. 2010 Jun;59(2):185-92. doi: 10.2332/allergolint.09-OA-0112. Epub 2010 Mar 25.
3
Eosinophilic airway disorders associated with chronic cough.与慢性咳嗽相关的嗜酸性气道疾病
Pulm Pharmacol Ther. 2009 Apr;22(2):114-20. doi: 10.1016/j.pupt.2008.12.001. Epub 2008 Dec 16.
4
ERS guidelines on the assessment of cough.欧洲呼吸学会咳嗽评估指南。
Eur Respir J. 2007 Jun;29(6):1256-76. doi: 10.1183/09031936.00101006.
5
Prognosis of cough variant asthma: a retrospective analysis.咳嗽变异性哮喘的预后：一项回顾性分析
J Asthma. 2006 Mar;43(2):131-5. doi: 10.1080/02770900500498477.
6
Characteristics of patients with chronic cough who developed classic asthma during the course of cough variant asthma: a longitudinal study.咳嗽变异性哮喘病程中发展为典型哮喘的慢性咳嗽患者的特征：一项纵向研究。
Respiration. 2005 Nov-Dec;72(6):606-11. doi: 10.1159/000087459. Epub 2005 Aug 11.
7
Effectiveness of montelukast in the treatment of cough variant asthma.孟鲁司特治疗咳嗽变异性哮喘的有效性
Ann Allergy Asthma Immunol. 2004 Sep;93(3):232-6. doi: 10.1016/S1081-1206(10)61493-7.
8
Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ).一种针对慢性咳嗽患者的症状特异性健康状况测量工具的开发：莱斯特咳嗽问卷（LCQ）。
Thorax. 2003 Apr;58(4):339-43. doi: 10.1136/thorax.58.4.339.
9
Comparison of atopic cough with cough variant asthma: is atopic cough a precursor of asthma?变应性咳嗽与咳嗽变异性哮喘的比较：变应性咳嗽是哮喘的前驱症状吗？
Thorax. 2003 Jan;58(1):14-8. doi: 10.1136/thorax.58.1.14.
10
Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma.白三烯受体拮抗剂扎鲁司特对咳嗽变异性哮喘患者的镇咳作用。
J Asthma. 2002 Jun;39(4):291-7. doi: 10.1081/jas-120002285.

一项开放标签、多机构、随机研究，旨在评估白三烯受体拮抗剂对接受吸入性糖皮质激素治疗的咳嗽变异性哮喘患者咳嗽评分的附加效应。

An Open-Label, Multi-Institutional, Randomized Study to Evaluate the Additive Effect of a Leukotriene Receptor Antagonist on Cough Score in Patients with Cough-Variant Asthma Being Treated with Inhaled Corticosteroids.

作者信息

Miwa Nanako, Nagano Tatsuya, Ohnishi Hisashi, Nishiuma Teruaki, Takenaka Kazuhiro, Shirotani Tomohiko, Nakajima Takeo, Dokuni Ryota, Kawa Yoshitaka, Kobayashi Kazuyuki, Funada Yasuhiro, Kotani Yoshikazu, Nishimura Yoshihiro

机构信息

Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Department of Respiratory Medicine, Akashi Medical Center, Akashi, Japan.

出版信息

Kobe J Med Sci. 2018 Dec 4;64(4):E134-E139.

PMID:30728339
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6347040/
Abstract

Cough-variant asthma is one of the most common reasons for chronic cough. It is important to treat appropriately cough-variant asthma because 30% to 40% of cough-variant asthma becomes a typical asthma. However, little is known about the treatment of cough-variant asthma except for inhaled corticosteroid (ICS). The aim of this study was to validate the additive efficacy of a leukotriene receptor antagonist (LTRA) on cough score and respiratory function in patients with cough-variant asthma being treated with ICS. A total 28 patients were randomly assigned to either an ICS + LTRA group or an ICS group. There were statistically significant improvements in cough scores in the ICS + LTRA group from 0 weeks (6.7 ± 4.4) to 2 weeks (2.9 ± 3.2) (P < 0.05), 4 weeks (0.7 ± 1.1) (P < 0.001), and 8 weeks (0.8 ± 1.2) (P < 0.001). However similar improvements were not evident in the ICS group from 0 weeks (6.7 ± 4.4) to 2 weeks (5.6 ± 10.0) (P = 0.59), 4 weeks (4.6 ± 7.6) (P = 0.32), and 8 weeks (2.9 ± 5.2) (P = 0.08). On the other hand, no significant changes were evident in the forced expiratory volume in 1 s (FEV1) and FEV1/forced vital capacity (FVC). In conclusion, the LTRA was useful in improving cough in patients with cough-variant asthma, even though it appeared to be ineffective in improving respiratory function.

摘要

咳嗽变异性哮喘是慢性咳嗽最常见的原因之一。恰当治疗咳嗽变异性哮喘很重要，因为30%至40%的咳嗽变异性哮喘会发展为典型哮喘。然而，除吸入性糖皮质激素（ICS）外，对于咳嗽变异性哮喘的治疗知之甚少。本研究的目的是验证白三烯受体拮抗剂（LTRA）对接受ICS治疗的咳嗽变异性哮喘患者咳嗽评分和呼吸功能的附加疗效。总共28例患者被随机分为ICS + LTRA组或ICS组。ICS + LTRA组的咳嗽评分从0周（6.7±4.4）到2周（2.9±3.2）（P<0.05）、4周（0.7±1.1）（P<0.001）和8周（0.8±1.2）（P<0.001）有统计学意义的改善。然而，ICS组从0周（6.7±4.4）到2周（5.6±10.0）（P = 0.59）、4周（4.6±7.6）（P = 0.32）和8周（2.9±5.2）（P = 0.08）没有明显类似的改善。另一方面，一秒用力呼气容积（FEV1）和FEV1/用力肺活量（FVC）没有明显变化。总之，LTRA有助于改善咳嗽变异性哮喘患者的咳嗽，尽管它似乎对改善呼吸功能无效。